1stOncology™: Cancer Intelligence Service – Page 8247 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

AusBiotech Conference

On October 19, 2021 Patrys CEO, Dr James Campbell, reported that it has composed some thoughts about his participation in AusBiotech’s upcoming events – the annual AusBiotech Conference (25-29 Oct 2021) and Australia Biotech Invest & Partnering Conference (26 Oct 2021) (Press release, Patrys, OCT 19, 2021, View Source [SID1234591499]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

There is no shortage of innovation in the biotech sector. Novel ideas and technologies abound, which makes it an exciting and inspiring space to operate. However, while new discoveries and opportunities are constantly emerging, these ideas rarely make it to market on the strength of science alone.

In my experience, the secret of success lies in the alignment of some key ingredients – the right technology, the right investors, and the right people – all at the right time. In short, great ideas attract great people. And great people attract financial capital.

Bringing people together is one of the key objectives of 2021 AusBiotech Conference. As a long-time participant, and now member of the AusBiotech board, I have seen firsthand the benefits of gathering the best and brightest within the life sciences community in one place. Industry events, such as the AusBiotech conference, are about encouraging conversation, sharing perspectives and strengthening connections, all of which are vital for the continuing growth and advancement of the Australian biotechnology sector.

This year I am honoured to be Chairing a session by international keynote speaker, Dr Niels Emmerich, Vice President, Global Head Search & Evaluation at AbbVie. Drawing on his vast experience, Dr Emmerich will provide valuable insights on what makes for successful research collaborations between academic institutions and biotech companies, and I encourage you to attend this session.

Keynote session overview:

"Current pharma models for accessing novel technologies: opportunities and challenges for biotechs and universities."

Sourcing and identifying novel technology – emerging best practice.
How do they get assessed?
What does stage-appropriate evidence look like?
Models for partnering when data is not mature enough for pharma licensing.
When: 9.00-9.30am AEDT, Thursday 28 Oct 2021
Where: Online / virtual webinar
Register: Click HERE to register for the AusBiotech Conference (25-29 Oct 2021)

I am also presenting on behalf of Patrys at the Australia Biotech Invest & Partnering Conference on Tuesday 26 October, where I’ll be sharing our latest investor presentation alongside other CEOs and executives , followed by a live 20-30 minute Q&A.

When: 9:45 – 11:15am AEDT, Tuesday 26 Oct 2021
Where: Online / virtual webinar
Register: Click HERE to register for the Australia Biotech Invest & Partnering Conference (26 Oct 2021)

Building and strengthening relationships have never been more important, and the virtual format of this year’s conference has made it easy for everyone to participate. I look forward to seeing you there – and joining the conversation online too – #AusBio21 #AusBioInv.

Wnt inhibitor XNW7201 in Evopoint obtained the ethical approval to conduct Phase IIa clinical trial

On October 18, 2021 Evopoint Biosciences reported XNW7201 approved by Beijing Cancer Hospital, the unit of the team leader, for the Phase IIa clinical trial on October 18, 2021 (Press release, Evopoint Biosciences, OCT 18, 2021, View Source [SID1234656283]).

Variation of Wnt signaling pathway is common in gastrointestinal tumors (e.g., gastric cancer, colorectal cancer, esophageal cancer, pancreatic cancer, etc.). Inhibition of Porcupine protein can block the abnormally activated Wnt signaling pathway. Moreover, it has been confirmed that the use of Wnt inhibitor is expected to enhance the effect of tumor immunotherapy. In this regard, Evopoint will continue to make every effort to promote the Phase IIa clinical trial of XNW7201 and strive to accelerate product launch for the benefit of numerous sufferers.

Huahui Health Closed Series A+ Financing

On October 18, 2021 Huahui Health reported completion of its Series A+ financing round back in March 2021, raising approximately CNY 500 million (Press release, Huahui Health, OCT 18, 2021, View Source [SID1234642183]). The A+ round was led by GL Ventures and joined by existing investors including Hankang Capital and Matrix Partners China. Raised fund will be used to support clinical development of its pipeline products, establishing pilot scale manufacturing for biologics, and building research platform for small molecules.

"This financing round will fuel and further expedite the growth and expansion of Huahui, " said Dr. Wenhui Li, founder of Huahui. "We are pleased with the recognition and support from our partners. We will continue building and advancing our internal competence and capabilities in order to meet the needs of patients across the globe."

Dragonfly Therapeutics Announces Sixth Dragonfly Drug to be Licensed by Bristol Myers Squibb and Receipt of Milestone Payments Following First Patient Dosing of Two TriNKET™ Immunotherapies Français

On October 18, 2021 Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, reported that Bristol Myers Squibb has licensed a fifth TriNKET Immunotherapy drug candidate, bringing the total drug candidates licensed by Bristol Myers Squibb to six including Dragonfly’s novel IL-12 cytokine DF6002/BMS-986415 (Press release, Dragonfly Therapeutics, OCT 18, 2021, View Source [SID1234596017]). Since their original 2017 collaboration focusing on hematology malignancies, the companies have agreed to two additional collaborations which include oncology and neuroinflammation targets.

Dragonfly also announced that the first patients have been dosed in Phase 1 clinical trials of both the CC-96191 and CC-92328 investigational immunotherapies, which are licensed to Bristol Myers Squibb. Following Dragonfly’s wholly-owned HER2-targeted NK cell engager therapy, DF1001, these are the second and third TriNKET drug candidates in the clinic, along with DF6002/BMS-986415 novel IL12-Fc fusion protein.

"We believe this recent opt-in decision by Bristol Myers Squibb further validates our drug discovery platform," said Bill Haney, Dragonfly’s CEO. "We are also delighted that Bristol Myers Squibb has brought our partnered targeted NK cell engager therapies to their first patients. The ongoing clinical trials of four Dragonfly-developed drugs, including our first cytokine, underscores the breadth of Dragonfly’s portfolio of innovative therapeutics, and the pace with which our team is bringing important new treatment options to patients with cancer and autoimmune disease."

The Phase 1 clinical trial for the CC-96191 TriNKET is a first-in-human study which will explore the safety, tolerability and preliminary biological and clinical activity of CC-96191 as a single-agent in the setting of relapsed or refractory acute myeloid leukemia (R/R AML). Additional information about the trial, including eligibility criteria, can be found at: View Source (ClinicalTrials.gov Identifier: NCT04789655).

The Phase 1 clinical trial for the CC-92328 TriNKET is a first-in-human study which will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM). Additional information about the trial, including eligibility criteria, can be found at: View Source (ClinicalTrials.gov Identifier: NCT04975399).

bluebird bio Sets Record Date and Distribution Date for Planned Business Separation

On October 18, 2021 bluebird bio, Inc. (NASDAQ: BLUE) reported that October 19, 2021 has been set as the record date for the dividend of shares of common stock of 2seventy to be distributed to bluebird stockholders in order to effect the separation of bluebird bio and 2seventy bio, Inc. into two independent, publicly traded companies (Press release, 2seventy bio, OCT 18, 2021, View Source [SID1234594669]).

Each bluebird bio stockholder of record as of the close of business on October 19, 2021 will receive, on the distribution date, one share of 2seventy common stock for every three shares of bluebird common stock held. The share dividend is expected to be distributed to bluebird stockholders on or about November 4, 2021. Following the separation, bluebird stockholders will also receive cash in lieu of any fractional shares of 2seventy common stock that those holders would have received after application of the 3:1 distribution ratio. No action is required by bluebird stockholders in order to receive the shares of 2seventy common stock in the dividend distribution.

Additionally, on October 18, 2021 the Securities and Exchange Commission declared 2seventy’s Registration Statement on Form 10 (the "Form 10") effective. This Form 10 contains further information regarding bluebird bio’s plans for a tax-free spin-off of its oncology programs and portfolio into 2seventy bio as a publicly traded company, including the conditions to completion of the separation.

"When-issued" trading for 2seventy common stock and "ex-distribution" trading for bluebird common stock is expected to commence on October 18, 2021 under the stock ticker symbols "TSVTV" and "BLUEV", respectively. A description of these expected trading markets is included in the Form 10. After the separation, 2seventy common stock is expected to trade on the Nasdaq Global Select Market under the stock ticker symbol "TSVT" and bluebird will continue to trade on Nasdaq Global Select Market under the stock ticker symbol "BLUE."